My 2 best US growth stocks to buy in November

I’ve just bought two US growth companies on my best stocks to buy now list, and I think they’re still terrific long-term bargains right now.

| More on:
Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Even after many US stocks have drastically increased so far this year, I’m still hunting for the best to buy and hold for the long term. And with a fresh earnings season revealing stronger performance on the back of improving economic conditions, a lot of new growth could be just around the corner.

I’ve already started topping up some of my existing portfolio positions as well as opening new ones. So, here are two of my latest stock purchases.

The powerhouse behind pharmaceuticals

Veeva Systems (NYSE:VEEV) is not a household name. But in the world of pharmaceuticals, it’s the platform that powers almost all of modern drug development. Veeva’s platform provides a comprehensive suite of applications designed to streamline the research and commercialisation processes of medicine while simultaneously ensuring regulatory compliance.

It’s effectively the Salesforce of the life sciences industry. And it’s used by 47 of the world’s 50 largest pharma companies including AstraZeneca and GSK. With revenue and earnings increasing by an average of 22% per year since 2019, the firm’s growth has been impressive. But more importantly, it’s been pretty consistent – a trend I expect to continue, given its industry-standard status.

However, one big risk I’m watching carefully is the recent announcement of Salesforce’s new life sciences CRM solution. Many of Veeva’s customers are still using the group’s old CRM system, which was built from the Salesforce platform.

The firm is currently migrating clients to its new proprietary Vault CRM to remove this dependency by 2030. However, if Salesforce’s new solution serves as a viable alternative, customers being forced to migrate might decide to switch sides instead.

Yet, replicating Veeva’s capabilities is no easy task, neither is penetrating its 85% global market share. That’s why, despite the rising competitive risk, I remain optimistic for the long run. And subsequently, I’ve just added more shares to my portfolio this month.

A fintech comeback story

During the 2022 stock market correction, PayPal (NASDAQ:PYPL) shares were hit hard, and more than 75% of the firm’s market cap was wiped out. While I think the sell-off was a bit overblown, there was some justifiable cause for concern both surrounding its valuation and bad communication from management.

Yet the shares are actually up 50% since July 2024. The recent third-quarter results were a bit of a mixed bag as revenue fell just short of expectations. However, they also revealed significant improvements in margins.

Total payment volume increased by 9% during the three-month period to $423bn, driven largely by increased activity among existing customers. This also translated into expanding profitability, enabling earnings per share to jump 22%, beating expectations.

It seems management’s tactics of maximising the value of its existing user base are creating value. And its also capitalised on its depressed valuation with $1.8bn in share buybacks.

There are still some important factors to keep an eye on. While overall profitability has increased, transaction margins are still facing the pressure of intense competition. And with the expected 2025 IPO of Revolut, among other new fintechs, this is a threat that’s not likely to disappear any time soon.

Nevertheless, with PayPal shares trading at a forward price-to-earnings ratio of just 18.2, the growth stock is priced attractively, in my opinion. That’s why it’s on my buy list and why I’ve just bought more.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has positions in PayPal and Veeva Systems. The Motley Fool UK has recommended AstraZeneca Plc, GSK, PayPal, Salesforce, and Veeva Systems. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 92% in a year! Is my biggest winner my best share to buy for 2025 too?

Harvey Jones got it spot on when he decided insurer Just Group was the best share to buy this time…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Down 29% to under £4 and with a P/B of just 1.2, is BP’s share price a must-buy opportunity for me?

BP’s share price has dropped in recent weeks, which raises the possibility of a bargain to be had in addition…

Read more »

Investing Articles

Shares in this iconic FTSE 250 car firm are down 53% this year, so is it time for me to buy?

This celebrated FTSE 250 car company has seen very tough times recently, but its Q3 results looked more positive, so…

Read more »

Investing Articles

What’s going on with the BT share price? Analysts say it’s undervalued

The BT share price has demonstrated plenty of volatility in 2024. Dr James Fox explain why this is and what…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

3 FTSE 250 stocks I’m considering buying for the long run

Our writer Ken Hall takes a look at three FTSE 250 stocks across different industries that he considers to be…

Read more »

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Up 75%! But is the IAG share price likely to crash in 2025?

The International Consolidated Airlines (IAG) share price has gone parabolic recently, but here's the potential danger ahead.

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

2 FTSE 100 shares with strong growth prospects for 2025

Sometimes the best growth prospects aren’t in the most obvious stocks. Stephen Wright looks at two FTSE 100 firms he…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Which Coca-Cola shares are best for dividend investors to consider?

When it comes to Coca-Cola shares, dividend investors are spoilt for choice. But what’s the difference between the UK-listed stocks…

Read more »